The BRAF mutation in lung cancer means that your cancer started due to a change in the BRAF gene. It may affect your treatment options and outlook. The BRAF gene is partially responsible for cell ...

"ASCO 2026: Interim data released for upcoming BRAF and RAS mCRC therapies" was originally created and published by Clinical ...

Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news. The recent approval by the ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...

BRAF is the most commonly mutated gene associated with melanoma, found in more than 50 percent of patients. The gene encodes a cytoplasmic kinase that is a member of the MAPK signal-transduction ...

Pfizer said Sunday its Braftovi-tied regimen nearly doubled the length of time colon cancer patients lived without getting sicker.

Predicting survival and metastasis in soft tissue sarcoma: A gene microarray study using RNA derived from archival paraffin-embedded tumours No significant financial relationships to disclose. This is ...

The BRAF gene encodes a serine/threonine kinase that lies at a pivotal node of the mitogen-activated protein kinase (MAPK) signalling cascade. Activating mutations—most notably the V600E ...

Frequently affected by so-called oncogenic mutations, BRAF is implicated in several human cancers. In its normal state, the BRAF protein remains confined to an inactive form, through a mechanism of ...

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...